Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Increased Second-line Eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Conventional Triple Therapy.

NCT01572597 is registered in ClinicalTrials.gov with Buddhist Tzu Chi General Hospital as lead sponsor.

NCT NCT01572597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01572597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Increased Second-line Eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Conventional Triple Therapy.
Lead sponsor
Buddhist Tzu Chi General Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
June 30, 2011
Completion date
December 31, 2012
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial infection due to helicobacter pylori (h. pylori)